[Registration Number 333-159147 PROSPECTUS 156,000,000 ORDINARY SHARES Our American depositary shares, or ADSs, are traded on the Nasdaq Global Select Market under the symbol “KONG.” On May 22, 2009, the last reported sale price of our ADSs was US$7.70 per ADS. Risk Factors Investing in these securities involves certain risks. See “ The date of this prospectus is May 26,]
[Form 10-Q x For the Quarterly Period Ended March 31, 2009 OR ¨ For the transition period from to Commission File No.: 001-34098 HONG KONG HIGHPOWER TECHNOLOGY, INC. Delaware 20-4062622 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Building A1, Luoshan Industrial Zone, Shanxia, Pinghu, Longgang, Shenzhen, Guangdong, 518111, People’s Republic of China (86) 755-89686238 (COMPANY’S]
[Form 10-Q x For the Quarterly Period Ended March 31, 2009 OR ¨ For the transition period from to Commission File No.: 001-34098 HONG KONG HIGHPOWER TECHNOLOGY, INC. Delaware 20-4062622 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Building A1, Luoshan Industrial Zone, Shanxia, Pinghu, Longgang, Shenzhen, Guangdong, 518111, People’s Republic of China (86) 755-89686238 (COMPANY’S]
[] [SUBSIDIARIES OF THE COMPANY Wholly-owned subsidiaries, each of which is duly incorporated in the PRC: Shenzhen Nepstar Pharmaceutical Electronic Technologies Ltd. Shenzhen Nepstar Commerce Development Ltd. Shenzhen Jinfu Logistics Service Co., Ltd. Shenzhen Wisconsin Trading Development Co., Ltd. Shenzhen Nepstar Pharmaceutical Co., Ltd. Consolidated entities, each of which is duly incorporated in the PRC: ] [I, Jiannong Qian, certify that: 1. I have reviewed this annual report on Form 20-F of China Nepstar Chain Drugstore Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [I, Ian F. Wade, certify that: 1. I have reviewed this annual report on Form 20-F of China Nepstar Chain Drugstore Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [I, William Weili Dai, certify that: 1. I have reviewed this annual report on Form 20-F of China Nepstar Chain Drugstore Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [Certification by the Co-Chief Executive Officer (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Jiannong Qian Co-Chief Executive Officer] [Certification by the Co-Chief Executive Officer (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Ian F. Wade Co-Chief Executive Officer] [Certification by the Chief Financial Officer (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. William Weili Dai Chief Financial Officer] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statement (No. 333-147702) on Form S-8 of China Nepstar Chain Drugstore Ltd. of our reports dated May 15, 2009, with respect to the consolidated balance sheets of China Nepstar Chain Drugstore Ltd. as of December 31, 2007 and 2008,]
[] [SUBSIDIARIES OF THE COMPANY Wholly-owned subsidiaries, each of which is duly incorporated in the PRC: Shenzhen Nepstar Pharmaceutical Electronic Technologies Ltd. Shenzhen Nepstar Commerce Development Ltd. Shenzhen Jinfu Logistics Service Co., Ltd. Shenzhen Wisconsin Trading Development Co., Ltd. Shenzhen Nepstar Pharmaceutical Co., Ltd. Consolidated entities, each of which is duly incorporated in the PRC: ] [I, Jiannong Qian, certify that: 1. I have reviewed this annual report on Form 20-F of China Nepstar Chain Drugstore Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [I, Ian F. Wade, certify that: 1. I have reviewed this annual report on Form 20-F of China Nepstar Chain Drugstore Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [I, William Weili Dai, certify that: 1. I have reviewed this annual report on Form 20-F of China Nepstar Chain Drugstore Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [Certification by the Co-Chief Executive Officer (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Jiannong Qian Co-Chief Executive Officer] [Certification by the Co-Chief Executive Officer (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Ian F. Wade Co-Chief Executive Officer] [Certification by the Chief Financial Officer (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. William Weili Dai Chief Financial Officer] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statement (No. 333-147702) on Form S-8 of China Nepstar Chain Drugstore Ltd. of our reports dated May 15, 2009, with respect to the consolidated balance sheets of China Nepstar Chain Drugstore Ltd. as of December 31, 2007 and 2008,]
[YEAR 2009 / 1 st QUARTER The following discussion of our financial condition and results of operations should be read in conjunction with the accompanying financial statements. Overview We are a leading business-to-business (B2B) media company and a primary facilitator of two-way trade with Greater China. The core business is facilitating trade from Greater China to the world, using a] [GLOBAL SOURCES LTD. AND SUBSIDIARIES At At March 31 December 31 2009 2008 (Unaudited) ASSETS Current Assets: Cash and cash equivalents $ 116,054 $ 70,225 Available-for-sale securities 20,674 60,786 Accounts receivable, net 5,019 6,025 Receivables from sales representatives 4,517 5,574 Inventory 996 1,306 Prepaid expenses and other current assets 20,177 16,513]
[YEAR 2009 / 1 st QUARTER The following discussion of our financial condition and results of operations should be read in conjunction with the accompanying financial statements. Overview We are a leading business-to-business (B2B) media company and a primary facilitator of two-way trade with Greater China. The core business is facilitating trade from Greater China to the world, using a] [GLOBAL SOURCES LTD. AND SUBSIDIARIES At At March 31 December 31 2009 2008 (Unaudited) ASSETS Current Assets: Cash and cash equivalents $ 116,054 $ 70,225 Available-for-sale securities 20,674 60,786 Accounts receivable, net 5,019 6,025 Receivables from sales representatives 4,517 5,574 Inventory 996 1,306 Prepaid expenses and other current assets 20,177 16,513]
[Registration Number 333-159147 PROSPECTUS 156,000,000 ORDINARY SHARES Our American depositary shares, or ADSs, are traded on the Nasdaq Global Select Market under the symbol “KONG.” On May 22, 2009, the last reported sale price of our ADSs was US$7.70 per ADS. Risk Factors Investing in these securities involves certain risks. See “ The date of this prospectus is May 26,]
